The short version of angiotensin IV fits in a sentence. The long version — which is the one that helps — is below.
Reviewed 2025-12-26. Anything still debated is marked as such rather than presented as settled.
Dihexa is a synthetic peptide studied in laboratory research. It is often described as an angiotensin IV analog or a hepatocyte growth factor mimetic. The compound emerged from investigations into angiotensin IV and its effects on neural pathways. It is not an approved medication, and controlled human trials are lacking. In literature and online forums, it is discussed mainly as a research chemical. Its chemical name appears as N-hexanoic-Tyr-Ile-(6-aminohexanoic amide) in some sources.
Development of dihexa has been linked to academic research on synaptogenesis, the formation of new synapses. Preclinical studies in rodents have examined its effects on learning and memory tasks. These studies are often cited in discussions about cognitive enhancement, but they do not establish safety or efficacy in humans. The compound's patent and commercial history is limited, and it is not widely available through pharmaceutical channels. Most information comes from animal models and in vitro experiments. Researchers continue to explore its basic biology rather than clinical applications.
Dihexa is not approved for human use in the United States or the European Union. It is commonly sold as a research chemical, a category that may not require the same regulatory review as medicines. Buyers should note that product labels may lack independent verification of identity or purity. The legal status can vary by country, and importation may be restricted. Reliable information about sourcing and quality is often scarce. Scientific publications typically use synthesized material from laboratories rather than commercial consumer products.
Chemically, dihexa is a short peptide-like molecule with nonstandard components. Its structure includes tyrosine and isoleucine residues linked to a hexanoic acid group and an aminohexanoic amide segment. This design distinguishes it from endogenous angiotensin IV, though the two are discussed together because of shared origins. Published summaries classify it as a small synthetic peptide with lipophilic features that may influence how it crosses biological barriers in experimental systems. Exact conformational details depend on the specific salt or free base form.
Regulatory treatment varies by country. Dihexa does not appear in major pharmacopeias as a licensed therapeutic substance. Suppliers may use labels such as research use only or not for human consumption. Such labels reflect legal and quality-control boundaries rather than evidence of clinical benefit. Importation, possession, and sale can be restricted depending on local laws, and enforcement focuses on claims, distribution channels, and product categories. These rules can change, and they differ from rules for approved medicines.
| Property | Value | Notes |
|---|---|---|
| CAS Registry Number | 1401708-83-5 | Identifier used in chemical databases. |
| Common synonyms | P21; N-hexanoic-Tyr-Ile-(6-aminohexanoic amide) | Names vary by supplier and publication. |
| Physical form | White to off-white powder | Lyophilized solid typical of peptides. |
| Solubility | Soluble in DMSO; limited in water | Aqueous preparation may need a co-solvent. |
| Storage | -20 °C, desiccated, protected from light | Reduce freeze-thaw cycles to maintain stability. |
Dihexa is a synthetic peptide derived from angiotensin IV, a naturally occurring fragment of the renin-angiotensin system. Researchers modified the angiotensin IV structure to improve metabolic stability and central nervous system activity. It is frequently described as a hepatocyte growth factor mimetic because it can activate the c-Met receptor pathway in experimental systems. Its development reflects interest in small peptides that influence synaptic plasticity and cognitive processes. Most information comes from preclinical studies rather than controlled human trials.
The compound has been examined in animal models for effects on learning, memory, and synaptic connectivity. Some reports describe increased dendritic spine density and improved performance on certain behavioral tasks after administration in rodents. These findings are often cited in discussions of nootropic research peptides, but replication across independent laboratories remains limited. The absence of published phase 1 or phase 2 clinical trial data makes it difficult to assess safety, effective routes, or long-term outcomes in humans. Consequently, claims about cognitive benefits in people remain speculative.
Dihexa is not approved as a medicine in major regulatory jurisdictions. It is commonly sold as a research chemical for laboratory use, though such products may not be standardized or independently verified. Scientific literature on dihexa includes in vitro assays, rodent studies, and reviews that discuss its proposed mechanism. The distinction between peer-reviewed findings and commercial promotion is important when evaluating available information. Open questions include its precise binding interactions, pharmacokinetics, and whether animal results translate to human biology.
The compound originated from work on angiotensin IV, a peptide fragment of the renin-angiotensin system. Researchers modified angiotensin IV-related structures to produce molecules with altered stability and activity. Dihexa emerged from that effort and was reported to promote dendritic spine growth in cultured neurons. Some studies link its effects to hepatocyte growth factor signaling and the c-Met receptor, while other work points to insulin-regulated aminopeptidase. The precise primary target remains a subject of investigation, and findings may depend on cell type, assay conditions, and species.
In animal research, dihexa has been administered through several routes, and reports describe improved performance on spatial learning and memory tasks in rodents. These results are frequently cited in discussions of nootropic compounds. However, species differences, small sample sizes, and varied testing protocols limit how far the findings can be generalized. No large randomized controlled trials in humans have established efficacy or long-term safety. Claims about human cognitive enhancement therefore remain speculative, and the compound is best described as an experimental laboratory substance rather than a proven therapeutic or supplement.
Dihexa is a synthetic compound studied in laboratory and animal models for effects on synaptic connectivity and cognitive performance. It is often described as a peptide analog because its structure incorporates amino acid residues linked to a hexanoic acid group. The molecule is not a naturally occurring human hormone or neurotransmitter. Its name appears in research literature and online discussions, but it has not been approved as a medicine by major regulatory agencies. Most information comes from preclinical experiments rather than controlled human trials.
Chemically, dihexa belongs to a broader group of angiotensin IV analogs. Researchers have modified the natural peptide to alter stability, binding, or distribution. Such changes can affect how the molecule behaves in experiments. The parent peptide angiotensin IV is involved in various physiological processes, but the modified analog is not identical to it. Public summaries sometimes blur the distinction between the natural fragment and the synthetic research compound. This distinction matters when interpreting study results.
Dihexa is a synthetic peptide that has been examined in laboratory and animal research. Its design is based on angiotensin IV, a naturally occurring peptide fragment produced in the body. The short name dihexa appears in scientific papers and online discussions, while the full chemical name describes a modified peptide chain. It is not a vitamin, mineral, or plant-derived compound. Suppliers typically present it as a research chemical rather than an approved medicine.
The full name often given is N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide. This name indicates a chain containing tyrosine, isoleucine, and a six-carbon amino acid derivative. Databases list a CAS Registry Number and a molecular formula for the compound. The peptide is small compared with proteins, and its structure allows it to be studied in cell cultures and animal models. Exact identity depends on the supplier's synthesis and purification process. Minor impurities can remain after synthesis.
== US–EU trade war == In response to Operation Arctic Endurance and European countries' refusal to support his annexation of Greenland, Trump threatened to increase tariffs against several EU and NATO members, reigniting concerns of a US-EU trade war. Trump said he would impose tariffs on any trading partner that did not support American annexation of Greenland. In January 2026, he threatened Denmark, Norway, Sweden, France, Germany, the United Kingdom, the Netherlands, and Finland with tariffs of up to 25% tariffs until they supported his takeover of Greenland, stating that they had "journeyed to Greenland, for purposes unknown. This is a very dangerous situation for the Safety, Security, and Survival of our Planet". On 21 January, Trump announced that he would not impose the tariffs, having agreed to a deal with NATO secretary general Mark Rutte.
No motivation to move or carry out activities of daily living Joint pain while stationary or in motion Tenderness or tightness in muscles Weaker muscles Reduced flexibility Unable to balance Higher chance of injury These signs and symptoms can be the determining factors for varying health conditions. However, they mainly align with hypomobility.
If consuming recovery drink after a workout, to maximize muscle protein anabolism, it is suggested that the recovery drink contain glucose (dextrose), protein (usually whey) hydrolysate containing mainly dipeptides and tripeptides, and leucine.
The dharmachakra is a symbol in the śramaṇa religion of Buddha Dhamma. Wheel symbolism was also used in Indian temples in places that underwent a religious transformation from Buddhism, such as Jagannath temple, whose deity is believed by some scholars to have a Buddhist origin. It also finds use in other ancient temples of Odisha, the most famous of which is the Konark Sun Temple. The 24 spoke Ashoka dharmachakra is present in the modern flag of India, representing the pan-Indian concept of Dharma. The modern State Emblem of India is a depiction of the Lion Capital of Ashoka (Sanchi), which includes the dharmachakra. An integral part of the emblem is the motto inscribed in Devanagari script: Satyameva Jayate (English: Truth Alone Triumphs). This is a quote from the Mundaka Upanishad, the concluding part of the Vedas. Sarvepalli Radhakrishnan, the first Vice President of India, stated that the Ashoka Chakra of India represents the "wheel of the law of dharma", as well as "Truth or satya", "Virtue" as well as "motion", as in the "dynamism of a peaceful change".
Sources: en.wikipedia.org
Such arrangements are less common than a random distribution of orientations would suggest, suggesting that this pattern is less stable than the anti-parallel arrangement, however bioinformatic analysis always struggles with extracting structural thermodynamics since there are always numerous other structural features present in whole proteins. Also proteins are inherently constrained by folding kinetics as well as folding thermodynamics, so one must always be careful in concluding stability from bioinformatic analysis. The hydrogen bonding of β-strands need not be perfect, but can exhibit localized disruptions known as β-bulges. The hydrogen bonds lie roughly in the plane of the sheet, with the peptide carbonyl groups pointing in alternating directions with successive residues; for comparison, successive carbonyls point in the same direction in the alpha helix.
=== Changes that occur during the onset of gingivitis and periodontitis and its role in bleeding on probing === Following the infiltration of bacteria and its products within the sulcular epithelium, the inflammatory response triggers the release of matrix metalloproteinases which cause collagen destruction. Studies suggest that this mechanism is through the activation of Toll-Like Receptors (TLRs, such as TLR-9) which are present on epithelial cells upon binding with bacterial products (such as lipopolysaccharides, unmyelinated CpG motifs). The expression of these collagenolytic matrix metalloproteinases like MMP-13 and activated NF-κB subunit p65 (a type of transcription factor) was more commonly present in periodontitis tissue compared to gingivitis tissue, indicating that the extent of connective tissue destruction accelerates with the progression of the disease. As an effort to curb the incoming bacterial invasion, the basal cells of the sulcular epithelium, being triggered by the ongoing inflammation, proliferate in hopes to maintain an intact barrier against the bacteria and their products. Due to the ongoing inflammation, engorgement of vessels and vasodilation occurs at the underlying connective tissue of the sulcular epithelium. The concurrent destruction of the collagen will then result in the thinning or ulceration of the sulcular epithelium, making the engorged and more abundant blood capillaries more susceptible to rupture upon innocuous mechanical stimuli (such as those during toothbrushing, probing, flossing, eating).
Lectins are carbohydrate-binding proteins that are highly specific for sugar groups that are part of sugars and other molecules. Lectins can recognize specific types of sugar moieties and play a role in the recognization of carbohydrates and glycosylated proteins. This recognition is used within organisms to mediate binding between specific cell types, to recognize chemical messages, and to recognize foreign cells: for example, the human lectin CLEC11A conveys a signal for bone growth. Lectins are also used by pathogens such as bacteria, viruses, and fungi to recognize and tightly attach to their host cells. Because lectin binds sugar moieties, it can "glue" together entities that have similar sugar moieties. Many cells have specific types of surface glycans; when a lectin is added, they become glued together or agglutinated. Glycoconjugates and polysaccharides that share similar moieties can likewise be glued together, making them precipitate out of a solution. By using the correct lectin, one can separate out entities that have a certain sugar moiety. This is useful for the determination of blood type and separating cells by type. Because a lectin molecule can only bind a handful of sugar groups, it can be disabled by an excess of the sugar group that it recognizes. Lectins are found in all domains and kingdoms of life, from the prokaryotes to the eukaryotes, from the plants to the animals.
Sources: en.wikipedia.org
Dihexa is a synthetic peptide investigated in preclinical research. It is often classified as an angiotensin IV analog or an HGF mimetic. It is not an approved medicine.
No. Regulatory agencies have not approved dihexa for human use. It is sold as a research chemical in some markets, and human safety and efficacy data are lacking.
Laboratory studies have examined its effects on synapse formation and cognitive tasks in animals. These are early-stage findings. They do not prove benefits or safety in people.
It is a synthetic peptide analog of angiotensin IV studied mainly in laboratory and animal research. It is not an approved medicine. Human clinical data are limited.